BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• 

  Job Trends

  California Tops Biopharma Job Openings So Far in 2024, Per BioSpace Data

  For the first eight months of 2024, California had the most job postings live on BioSpace—37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period.

  September 12, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Pipeline

  Moderna Slashes Annual R&D Budget by $1.1B, Eyes 10 Approvals Through 2027

  In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending, while pushing back its target for breaking even by two years to 2028.

  September 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  AI Promises: Funding Data Literacy and Reality First

  In this episode, Lori and guests discuss practical approaches regarding artificial intelligence and investor and industry confidence in its current state.

  September 12, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Approvals

  J&J Positions Tremfya as Stelara Successor With FDA Nod for Ulcerative Colitis

  Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.

  September 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care

  An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

  September 12, 2024

   · 

  3 min read

   · 

  Jill Marie Drury
• 

  Weight loss

  Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data

  When doses were increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal distension.

  September 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal

  Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.

  September 12, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Adcomms

  Intercept’s Ocaliva in Jeopardy as FDA Questions Efficacy, Safety Ahead of Adcomm

  With a Friday advisory committee meeting looming, the sole indication for Intercept Pharmaceuticals’ Ocaliva appears to be at risk as the regulator flags issues regarding its post-marketing results.

  September 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  BridgeBio Grows Up, Trims Pipeline as It Leans Into Late-Stage Assets

  As it nears a crucial FDA action date for its transthyretin amyloid cardiomyopathy candidate, BridgeBio focuses on its late-stage pipeline.

  September 12, 2024

   · 

  4 min read

   · 

  Heather McKenzie
• Press Releases

  Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

  September 12, 2024

   · 

  15 min read